← All Castle Biosciences INC filings

Castle Biosciences INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
CSTL
Castle Biosciences INC
DEF: Castle Biosciences 2026 Annual Meeting Proxy Statement
Castle Biosciences invites stockholders to its 2026 Annual Meeting on May 28, 2026, to vote on director elections, auditor ratification, executive compensation, and director compensation policy.
NASDAQ
CSTL
Castle Biosciences INC
DEFA14A: Castle Biosciences, Inc. Files Definitive Proxy Statement
Castle Biosciences, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
CSTL
Castle Biosciences INC
DEF: Castle Biosciences Reports Strong 2024 Revenue Growth, Sets Stage for 2025 Annual Meeting
Castle Biosciences announces a 51% revenue increase for 2024, exceeding guidance, and invites stockholders to the 2025 Annual Meeting.
NASDAQ
CSTL
Castle Biosciences INC
DEFA14A: Castle Biosciences Addresses Stockholder Concerns on Executive Pay, Urges 'For' Vote on Say-on-Pay Proposal
Castle Biosciences issues a letter to stockholders highlighting changes made to executive compensation in response to stockholder feedback, urging a vote in favor of the Say-on-Pay proposal at the upcoming Annual Meeting.
NASDAQ
CSTL
Castle Biosciences INC
DEFA14A: Castle Biosciences, Inc. Files Definitive Proxy Statement
Castle Biosciences, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
CSTL
Castle Biosciences INC
DEF 14A: Castle Biosciences Aims for Continued Growth: Outlines Strategy in 2024 Proxy Statement
Castle Biosciences' 2024 Proxy Statement highlights the company's strong 2023 performance and outlines its strategy for continued growth and value creation.